Related Experiment Video
Updated: Feb 5, 2026

Studying Brain Function in Children Using Magnetoencephalography
Published on: April 8, 2019
[Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia]
Olga Morales-Múnera1, Ángela Pedraza, Laura Niño-Serna
1Hospital San Vicente Fundación, Departamento de Pediatría, Medellín, Colombia. lavusnino@gmail.com.
Insights
Omalizumab significantly improved asthma symptoms in children over 6 years old in real-world use. This add-on therapy reduced controller medication needs and corticosteroid dosages, demonstrating its effectiveness and safety.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Pharmacology
Background:
- Controlled trials confirm omalizumab's efficacy and safety in children over 6 with asthma.
- Limited real-world studies exist for this demographic.
Purpose of the Study:
- To evaluate omalizumab's effectiveness as an add-on therapy for moderate to severe persistent asthma in children under real-life conditions.
- To assess symptom response and changes in medication use.
Main Methods:
- An observational study with 12-month real-life follow-up.
- 61 children over 6 years old with moderate to severe persistent asthma were assessed.
- Asthma control was evaluated before treatment and at 4 and 12 months.
Main Results:
- Significant symptom improvement observed after 12 months of omalizumab treatment (p = 0.001).
- Controller drug consumption decreased in 73% of patients; inhaled corticosteroid doses were reduced in 61% and discontinued in 8%.
- Average inhaled corticosteroid dose significantly decreased (p = 0.02).
Conclusions:
- Omalizumab is an effective, safe, and well-tolerated add-on therapy for achieving clinical control in moderate to severe allergic asthma.
- It provides significant benefits for children whose asthma is not adequately managed by standard therapies.
Background:
Omalizumab efficacy and safety in children older than 6 years has been clearly demonstrated in controlled clinical trials, but only in few real-life studies.
Objective:
To assess the response with omalizumab addition in children with moderate to severe persistent asthma in real-life conditions.
Methods:
Observational study with a 12-month real-life follow-up in a group of 61 children older than 6 years who were assessed for asthma control before treatment was started and at 4 and 12 months.
Results:
After 12 months of treatment with omalizumab, there was symptom improvement both for those younger and older than 12 years (p = 0.001). There was a decrease in controller drug consumption in 73% of patients; in 61%, inhaled corticosteroid dose was reduced, and 8% discontinued its use. Inhaled corticosteroid average dose was decreased to 396 ± 298 µg, with this being statistically significant (p = 0.02).
Conclusion:
Omalizumab is an efficacious, safe and well-tolerated drug as add-on therapy for clinical control of moderate and severe allergic asthma that has not improved with standard therapies.
More Related Videos
Related Concept Videos
Half-life of a Reaction
Characteristics of Life
Asthma-I: Introduction
The Angiosperm Life Cycle
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

